menu search

ILMN / Illumina Stock: Exceptional Growth Marred By Contentious Acquisition

In August 2021, Illumina completed the GRAIL acquisition despite the ongoing regulatory investigations in the EU and US. In the event of court losses, ILMN faces the risk of paying massive fines of $400M, in addition to divesting GRAIL in 2025 or 2026. Read More
Posted: Jan 31 2022, 18:38
Author Name: Seeking Alpha
Views: 111227

ILMN News  

LGND vs. ILMN: Which Stock Is the Better Value Option?

By Zacks Investment Research
October 26, 2023

LGND vs. ILMN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina ( more_horizontal

Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?

By Zacks Investment Research
October 20, 2023

Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately. more_horizontal

Activist Icahn sues Illumina board over Grail acquisition - FT

By Reuters
October 17, 2023

Activist Icahn sues Illumina board over Grail acquisition - FT

Activist-investor Carl Icahn said his firm had sued current and former board directors at Illumina concerning the acquisition of gene-sequencing compa more_horizontal

Illumina responds to EC Grail divestiture order

By Market Watch
October 13, 2023

Illumina responds to EC Grail divestiture order

Illumina Inc. ILMN, -1.10% responded Friday to an order it received Thursday from the European Commission directing the company to divest its $7.1 bil more_horizontal

Illumina to divest cancer test maker Grail if it does not win challenge in EU court

By Reuters
October 13, 2023

Illumina to divest cancer test maker Grail if it does not win challenge in EU court

Illumina said on Friday it would divest cancer test maker Grail in 12 months, according to the terms of the order by the European Commission, if it do more_horizontal

Illumina ordered by European Commission to sell cancer test maker Grail

By Proactive Investors
October 12, 2023

Illumina ordered by European Commission to sell cancer test maker Grail

Illumina Inc (NASDAQ:ILMN), a genetic testing company, has been ordered by EU antitrust regulators to sell Grail after closing its takeover of the can more_horizontal

Illumina ordered by EU antitrust regulators to sell Grail

By Reuters
October 12, 2023

Illumina ordered by EU antitrust regulators to sell Grail

U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail after it completed the deal before s more_horizontal

Illumina to divest Grail if it loses final court appeals

By Reuters
October 11, 2023

Illumina to divest Grail if it loses final court appeals

Illumina Inc said on Wednesday it will divest Grail if the company loses the final appeals in U.S. or European courts. more_horizontal


Search within

Pages Search Results: